HALOZYME THERAPEUTICS, INC.
HALOZYME THERAPEUTICS, INC. (HALO): 5 pipeline candidates · 2 upcoming catalysts · ~19 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
18.7 months
D/E 11.17 · 4% dilution
Lead: Approved
5 candidates
2 upcoming, next in ~1352d
0 buys · 47 sells (180d)
A transparent, data-derived signal for HALOZYME THERAPEUTICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$8.2B
Cash
$312.0M
Quarterly Burn
$83.4M
Runway
18.7 mo
Revenue
$376.7M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (5 candidates)
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
630
Total value held
$7.49B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 13,265,053 | $857.3M |
| vanguard capital management llc | 10,542,436 | $681.4M |
| vanguard portfolio management llc | 5,249,206 | $339.3M |
| state street corp | 4,937,854 | $319.1M |
| bank of america corp /de/ | 2,913,109 | $188.3M |
| morgan stanley | 2,562,309 | $165.6M |
| william blair investment management, llc | 2,525,975 | $163.3M |
| geode capital management, llc | 2,505,786 | $162.0M |
| janus henderson group plc | 2,467,316 | $159.5M |
| snyder capital management l p | 2,323,077 | $150.1M |
Showing top 10 of 630 institutional holders of HALOZYME THERAPEUTICS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in HALOZYME THERAPEUTICS, INC.'s pipeline?
HALOZYME THERAPEUTICS, INC. (HALO) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is HALOZYME THERAPEUTICS, INC.'s next catalyst?
HALOZYME THERAPEUTICS, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Open-Label, Multiple-Dose, 52-Week Study + 24-Month Long-Term Safety Extension to Evaluate the Safet" — expected March 1, 2030.
What is HALOZYME THERAPEUTICS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, HALOZYME THERAPEUTICS, INC. has approximately 18.7 months of cash runway.
What is HALOZYME THERAPEUTICS, INC.'s market capitalization?
HALOZYME THERAPEUTICS, INC.'s market capitalization is approximately $8.2B.
Who is the CEO of HALOZYME THERAPEUTICS, INC.?
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. is the chief executive officer of HALOZYME THERAPEUTICS, INC. (HALO).
Get the full picture on HALOZYME THERAPEUTICS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.